Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 2/20 | 0.63 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.63 |
| ▸ | DRD1 | P21728 | 2/20 | 0.63 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.63 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.63 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.63 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.63 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.63 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.63 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.63 |
| ▸ | HTR2A | P28223 | 1/20 | 0.63 |
| ▸ | HRH1 | P35367 | 1/20 | 0.63 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.61 |
| ▸ | LMNA | P02545 | 1/20 | 0.61 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.58 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 4/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14220155 | 0.87 | MEN1 (0.56) | CHRM2ADRA2ADRD1SLC6A2SLC6A4 | |
| SCHEMBL1276585 | 0.84 | CHRM2 (0.59) | CHRM2ADRA2ADRD1SLC6A2SLC6A4 | |
| SCHEMBL8805352 | 0.84 | CHRNB2 (0.59) | CHRM2ADRA2ADRD1SLC6A2SLC6A4 | |
| SCHEMBL8250244 | 0.84 | CHRM2 (0.48) | CHRM2ADRA2ADRD1SLC6A2SLC6A4 | |
| SCHEMBL8283845 | 0.84 | ALDH1A1 (0.62) | CHRM2ADRA2ADRD1SLC6A2SLC6A4 | |
| SCHEMBL19501378 | 0.83 | GAA (0.52) | CHRM2ADRA2ADRD1SLC6A2SLC6A4 | |
| SCHEMBL8362958 | 0.83 | LMNA (0.68) | CHRM2ADRA2ADRD1SLC6A2SLC6A4 | |
| SCHEMBL19513572 | 0.83 | TSHR (0.50) | CHRM2ADRA2ADRD1SLC6A2SLC6A4 | |
| SCHEMBL15131433 | 0.82 | HIF1A (0.46) | CHRM2ADRA2ADRD1SLC6A2SLC6A4 | |
| SCHEMBL6184529 | 0.82 | HIF1A (0.49) | CHRM2ADRA2ADRD1SLC6A2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115999456-A | Reactive distillation equipment for continuously producing linalyl acetate and method for continuously producing linalyl acetate | 万华化学集团股份有限公司 | 2023-04-25 | — | — | CN | disclosed |
| EP-3943490-A1 | 1-CYANO-PYRROLIDINE COMPOUNDS AS USP30 INHIBITORS | Mission Therapeutics Limited (GB) | 2022-01-26 | — | — | EP | disclosed |
| US-11066365-B2 | 1-cyano-pyrrolidine compounds as USP30 inhibitors | MISSION THERAPEUTICS LIMITED (GB) | 2021-07-20 | — | — | US | disclosed |
| EP-3277677-B9 | 1-CYANO-PYRROLIDINE COMPOUNDS AS USP30 INHIBITORS | MISSION THERAPEUTICS LTD (GB) | 2021-07-14 | — | — | EP | disclosed |
| US-11053198-B2 | 1-cyano-pyrrolidine compounds as USP30 inhibitors | MISSION THERAPEUTICS LIMITED (GB) | 2021-07-06 | — | — | US | disclosed |
| EP-3842427-A1 | 1-CYANO-PYRROLIDINE COMPOUNDS AS USP30 INHIBITORS | Mission Therapeutics Limited (GB) | 2021-06-30 | — | — | EP | disclosed |
| US-10689345-B2 | 1-cyano-pyrrolidine compounds as USP30 inhibitors | MISSION THERAPEUTICS LIMITED (GB) | 2020-06-23 | — | — | US | disclosed |
| US-20200181086-A1 | 1-CYANO-PYRROLIDINE COMPOUNDS AS USP30 INHIBITORS | MISSION THERAPEUTICS LIMITED (GB) | 2020-06-11 | — | — | US | disclosed |
| US-20190322624-A1 | 1-CYANO-PYRROLIDINE COMPOUNDS AS USP30 INHIBITORS | MISSION THERAPEUTICS LIMITED (GB) | 2019-10-24 | — | — | US | disclosed |
| US-20190284138-A1 | 1-CYANO-PYRROLIDINE COMPOUNDS AS USP30 INHIBITORS | MISSION THERAPEUTICS LIMITED (GB) | 2019-09-19 | — | — | US | disclosed |
| EP-1303507-A1 | PYRIMIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2003-04-23 | — | — | EP | disclosed |
| EP-1202626-A4 | ALPHA-HYDROXY-GAMMA-[[(CARBOCYCLIC-OR HETEROCYCLIC-SUBSTITUTED)AMINO]CARBONYL]ALKANAMIDE DERIVATIVES AND USES THEREOF | MERCK & CO INC (US) | 2002-10-30 | — | — | EP | disclosed |
| EP-1202626-A1 | ALPHA-HYDROXY-GAMMA-[[(CARBOCYCLIC-OR HETEROCYCLIC-SUBSTITUTED)AMINO]CARBONYL]ALKANAMIDE DERIVATIVES AND USES THEREOF | Merck & Co., Inc. (US) | 2002-05-08 | — | — | EP | disclosed |
| WO-2002006271-A1 | PYRIMIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2002-01-24 | — | — | WO | disclosed |
| WO-2001005230-A1 | ALPHA-HYDROXY-GAMMA-[[(CARBOCYCLIC-OR HETEROCYCLIC-SUBSTITUTED)AMINO]CARBONYL]ALKANAMIDE DERIVATIVES AND USES THEREOF | MERCK & CO., INC. (US) | 2001-01-25 | — | — | WO | disclosed |
| EP-0625507-B1 | Urea derivatives and their use as acat inhibitors | NISSHIN FLOUR MILLING CO (JP) | 1997-07-23 | — | — | EP | disclosed |
| US-5621010-A | ANTIHYPERCHOLESTEROLEMIA AND ANTIATHEROSCLEROSIS | NISSHIN FLOUR MILLING CO., LTD. (JP) | 1997-04-15 | — | — | US | disclosed |
| EP-0625507-A2 | Urea derivatives and their use as acat inhibitors | NISSHIN FLOUR MILLING CO., LTD. (JP) | 1994-11-23 | — | — | EP | disclosed |
| US-4006239-A | Benzoic acid amides for mycobacterium infections | BAYER AKTIENGESELLSCHAFT (DT) | 1977-02-01 | — | — | US | disclosed |
| US-3995044-A | Pyridine carboxylic acid amides for mycobacterium infections | BAYER AKTIENGESELLSCHAFT (DT) | 1976-11-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11066365-B2 | 1-cyano-pyrrolidine compounds as USP30 inhibitors | USP30, USP20, USP10 | CHRM2 3107/4885ADRA2A 4437/4885DRD1 2227/4885 |
| US-11053198-B2 | 1-cyano-pyrrolidine compounds as USP30 inhibitors | USP30, USP20, USP10 | CHRM2 3254/4885ADRA2A 4584/4885DRD1 2251/4885 |
| US-20200181086-A1 | 1-CYANO-PYRROLIDINE COMPOUNDS AS USP30 INHIBITORS | USP30, USP20, USP10 | CHRM2 3404/4885ADRA2A 4661/4885DRD1 2184/4885 |
| US-20190284138-A1 | 1-CYANO-PYRROLIDINE COMPOUNDS AS USP30 INHIBITORS | USP30, USP20, USP10 | CHRM2 3107/4885ADRA2A 4437/4885DRD1 2227/4885 |
| US-20190322624-A1 | 1-CYANO-PYRROLIDINE COMPOUNDS AS USP30 INHIBITORS | USP30, USP20, USP10 | CHRM2 3254/4885ADRA2A 4584/4885DRD1 2251/4885 |
| US-10689345-B2 | 1-cyano-pyrrolidine compounds as USP30 inhibitors | USP30, USP20, USP10 | CHRM2 3254/4885ADRA2A 4584/4885DRD1 2251/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.